December 28, 2014 6:11 AM ET

Pharmaceuticals

Company Overview of Merck Research Laboratories

Company Overview

Merck Research Laboratories discovers and develops medicines for cancer and neurodegenerative disorders. The company was founded in 2004 and is based in Boston, Massachusetts. Merck Research Laboratories operates as a subsidiary of Merck & Co. Inc.

33 Avenue Louis Pasteur

Boston, MA 02115

United States

Founded in 2004

Phone:

617-992-2000

Key Executives for Merck Research Laboratories

President
Age: 62
Senior Vice President and Franchise Head of Immunology Respiratory & Endocrine
Age: 60
Senior Vice President and Franchise Head of Diabetes & Obesity
Senior Vice President and Head of Franchise
Age: 58
Head of Site
Age: 59
Compensation as of Fiscal Year 2014.

Merck Research Laboratories Key Developments

BIND Therapeutics, Inc. Announces Agreement with Merck to Develop Targeted Accurin Nanomedicines for Oncology

BIND Therapeutics, Inc. announced a joint research and development agreement with Merck, through a subsidiary to discover and develop novel nanomedicines for oncology. This collaboration will leverage BIND's proprietary nanomedicine technology to create targeted Accurins based on novel, potent payloads from Merck's preclinical oncology portfolio. The first two Merck compounds include a kinesin spindle protein (KSP) inhibitor and a polo-like kinase 1 (PLK1) inhibitor. Both KSP and PLK1 are regulators of cellular mitosis and are considered essential to the proliferation of cancer cells. These pathways have proven difficult to target effectively using conventional agents due to therapeutic index limitations. Under the terms of the agreement, BIND will apply its Medicinal Nanoengineering(R) platform to develop targeted Accurins based initially on Merck-supplied investigational KSP and PLK1 inhibitors. The agreement also includes the option to incorporate additional Merck compounds in the future. BIND will fund and conduct research and development activities to advance Accurin product candidates based on these agents through first-in-human clinical studies, after which Merck and BIND will alternate in choosing whether or not to further develop and commercialize the Accurin products. If BIND opts in, in most scenarios there will be no payments made to Merck beyond a royalty on future product sales. If Merck opts in, it will pay BIND a fee based on a multiple of BIND's research and development expenses, plus a royalty on future product sales. Further terms of the agreement were not disclosed.

Merck Research Laboratories Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 through Sep-24-2014

Merck Research Laboratories Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 through Sep-24-2014. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Presentation Date & Speakers: Sep-22-2014, John Delyani, Executive Director, Business Development and Licensing. Sep-24-2014, Benjamin Thorner, Associate VP, Head of Business Development and Licensing, Boston Innovation Hub.

Merck Research Laboratories Announces Encouraging Data from Phase Ib Melanoma Study

Merck Research Laboratories has announced encouraging data from its ongoing Phase Ib study, KEYNOTE-001, evaluating pembrolizumab, its investigational anti-PD-1 antibody, as a single agent in 411 patients with advanced melanoma. Following treatment with pembrolizumab, the estimated overall survival (OS) rate at one year was 69% across all patients studied, including 74% in patients without prior ipilimumab therapy (current standard therapy) and 65% in patients who had progressive disease on or following ipilimumab. At 18 months, the estimated OS was 62%. The median OS has not been reached, with some patients receiving treatment with pembrolizumab as monotherapy for more than two years. These data from 411 patients with advanced melanoma enrolled in multiple cohorts from KEYNOTE-001 will be highlighted as part of the ASCO 2014 Press Program. KEYNOTE-001 involved seven advanced melanoma cohorts including patients with varying stages of disease and prior lines of therapy. At baseline, 56% of patients had the most advanced stage of disease (M1c) (n=232) and 77% of patients had received at least one prior systemic therapy (n=316). At the time of analysis, 88% of reported responses in evaluable patients were ongoing and the median duration of response, by RECIST criteria, had not been reached (n=115/130) (range 6+ weeks to 76+ weeks). The median progression-free survival (PFS), by RECIST criteria, was 5.5 months overall (95% CI, 3.8-6.2), including 5.6 months in patients with no prior ipilimumab therapy (95% CI, 3.7-11) and 5.4 months in patients who had progressive disease on or following ipilimumab therapy (95% CI, 3.2-5.6). Anti-tumor activity was observed across all doses studied, regardless of the type and number of previous treatments (including prior ipilimumab therapy), performance status, Lactate Dehydrogenase (LDH) levels, BRAF mutation status, tumor size at baseline, and anatomical site of metastatic disease. An analysis of patient subgroups indicates that lower tumor burden at baseline is a strong predictor of response to pembrolizumab.

Similar Private Companies By Industry

Company Name Region
HPL Biomedical, Inc. United States
Shionogi Pharma, Inc. United States
MBF Therapeutics, Inc. United States
Polaris Pharmaceuticals, Inc. United States
Allergan USA, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Merck Research Laboratories, please visit www.merck.com/mrl. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.